Published 09:26 IST, March 8th 2024
US FDA grants expanded approval for BeiGene's blood cancer drug
According to BeiGene, the US wholesale acquisition cost for Brukinsa stands at $15,066 for a 30-day supply, with consistent pricing across all indicated uses.
Cancer drug | Image:
Unsplash
Advertisement
09:26 IST, March 8th 2024